Patient advocacy helps patients weigh up gene therapy trial risk/benefits Cover

.blurhash-client-img { display: none !important; }

Patient advocacy helps patients weigh up gene therapy trial risk/benefits

The Journal of Haemophilia Practice

Volume 2 (2015): Issue 1 (March 2015)

By: John Morris

Open Access

|Apr 2018

References

1. Nathwani AC, Tuddenham EG, Rangarajan S, et al. AdenovirusPassociated virus vectorPmediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357P65. doi: 10.1056/NEJMoa1108046.
Open DOI Search in Google Scholar Back to article
2. Nathwani AC, Reiss UM, Tuddenham EG, et al. LongPterm safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994P2004. doi: 10.1056/NEJMoa1407309.
Open DOI Search in Google Scholar Back to article

DOI: https://doi.org/10.17225/jhp.00040 | Journal eISSN: 2055-3390

Journal RSS Feed

Language: English

Page range: 6 - 8

Published on: Apr 21, 2018

Published by: Haemnet Ltd

In partnership with: Paradigm Publishing Services

Publication frequency: 1 issue per year

Keywords:

Christmas Disease,

informed consent

Related subjects:

Basic medical science,

Basic medical science, other,

Clinical medicine,

Clinical medicine, other,

© 2018 John Morris, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 2 (2015): Issue 1 (March 2015)Next article